This article is more than 5 years old. Information may no longer be current.

Iluvien receives marketing authorization in Germany for treatment of chronic DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Federal Ministry of Health of Germany has granted marketing authorization to Alimera Sciences for Iluvien sustained-release fluocinolone acetonide for treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies, according to a news release.

The sustained-release intravitreal implant delivers sub-microgram levels of fluocinolone acetonide for up to 36 months, the release said.

"We are very pleased to receive German marketing authorization for Iluvien, our fifth of seven expected approvals in the European Union," Dan Myers, president and chief executive officer of Alimera Sciences, said in the release. "Assuming the closing of our recently announced financing, we anticipate that we will launch Iluvien in Germany during the first quarter of 2013."

Iluvien had already been granted marketing authorization in Austria, France, Portugal and the United Kingdom.